Vimentin-positive and Alpha-fetoprotein-elevated Nuclear Protein of the Testis Midline Carcinoma: A Case Report and Review of the Literature.
AFP
NUT midline carcinoma
chemotherapy
vimentin
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
15 Nov 2021
15 Nov 2021
Historique:
pubmed:
1
6
2021
medline:
17
11
2021
entrez:
31
5
2021
Statut:
ppublish
Résumé
Nuclear protein of the testis (NUT) midline carcinoma (NMC) is a rare malignant tumor expressing NUT with BRD4/3 rearrangements and is sometimes misdiagnosed as germinoma, especially in alpha-fetoprotein (AFP)-elevated cases. A 28-year-old man had a mediastinal tumor with multiple bone metastases and elevated AFP levels. Imaging/laboratory findings led to a pathological diagnosis of extragonadal germinoma. After unsuccessful treatment with etoposide-cisplatin, he was re-diagnosed with sarcoma due to vimentin-positive findings. He was treated with adriamycin-ifosfamide, which resulted in disease-control. A posthumous examination clarified the NUT rearrangement. Even in cases with characteristic findings, such as elevated AFP levels and vimentin positivity, NMC should be considered as a differential diagnosis. We note, however, that adriamycin-ifosfamide has some efficacy in such cases.
Identifiants
pubmed: 34053984
doi: 10.2169/internalmedicine.7019-21
pmc: PMC8666212
doi:
Substances chimiques
BRD4 protein, human
0
Cell Cycle Proteins
0
Nuclear Proteins
0
Oncogene Proteins
0
Oncogene Proteins, Fusion
0
Transcription Factors
0
Vimentin
0
alpha-Fetoproteins
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3645-3649Références
J Clin Oncol. 2005 Sep 20;23(27):6549-55
pubmed: 16170162
Cancer Discov. 2014 Aug;4(8):928-41
pubmed: 24875858
Pathol Res Pract. 2014 Jun;210(6):383-8
pubmed: 24655834
Sci Rep. 2018 Mar 14;8(1):4482
pubmed: 29540837
N Engl J Med. 1987 Jun 4;316(23):1435-40
pubmed: 2437455
Genes Dev. 2015 Jul 15;29(14):1507-23
pubmed: 26220994
Cancer. 2016 Dec 1;122(23):3632-3640
pubmed: 27509377
Clin Cancer Res. 2012 Oct 15;18(20):5773-9
pubmed: 22896655
Am J Surg Pathol. 1986 Aug;10(8):560-7
pubmed: 2426981
Am J Surg Pathol. 2009 Jul;33(7):984-91
pubmed: 19363441
Ann Intern Med. 1986 Apr;104(4):547-53
pubmed: 3006571
Gynecol Oncol Case Rep. 2012 Oct 08;3:1-3
pubmed: 24371650
Oncogene. 2008 Apr 3;27(15):2237-42
pubmed: 17934517
Arch Pathol Lab Med. 2011 Nov;135(11):1494-8
pubmed: 22032580
J Surg Oncol. 2010 Sep 1;102(3):249-55
pubmed: 20740583
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2721-30
pubmed: 24979794
BMC Cancer. 2017 Apr 13;17(1):266
pubmed: 28407756
J Thorac Oncol. 2013 Oct;8(10):1335-8
pubmed: 24457244
Cancer Genet Cytogenet. 2010 Nov;203(1):16-20
pubmed: 20951314
Pediatr Blood Cancer. 2017 Dec;64(12):
pubmed: 28643357
J Natl Compr Canc Netw. 2018 May;16(5):467-472
pubmed: 29752320
BMC Cancer. 2016 Nov 17;16(1):895
pubmed: 27855672
Expert Rev Anticancer Ther. 2015;15(10):1199-213
pubmed: 26402248
Anticancer Res. 2015 Mar;35(3):1607-12
pubmed: 25750317
Cochrane Database Syst Rev. 2003;(3):CD003293
pubmed: 12917960
Cytopathology. 2011 Dec;22(6):414-7
pubmed: 21210877
J Clin Oncol. 2016 May 10;34(14):e126-9
pubmed: 24733790
Cancer Res. 1975 Apr;35(4):991-6
pubmed: 46783
Chest. 1983 Feb;83(2):263-7
pubmed: 6185280
J Clin Oncol. 1985 May;3(5):666-71
pubmed: 2582097
Cancer Res. 2003 Jan 15;63(2):304-7
pubmed: 12543779